AstraZeneca (AZN) reported a second-quarter earnings beat, raising its full-year guidance. However, with the upcoming US election potentially impacting operations in regions like China, AstraZeneca CEO Pascal Soriot joins Yahoo Finance reporter Anjalee Khemlani on Catalysts to discuss the company's strategy for navigating these challenges.

Soriot outlines AstraZeneca's approach to global expansion, particularly regarding supply chains. He explains that the company is developing two distinct supply chains: one serving Western countries and another "targeted at supplying China and some emerging markets." Importantly, he emphasizes that these two supply chains — the US vs China — will operate "relatively independent from each other."

Addressing concerns about the US election's potential impact on operations in China, Soriot notes the company's strategic separation of research and development from manufacturing. This approach allows the company to "source innovation from one part of the world or the other." He acknowledges the diverse policies and rules across different regions, stating that the company adapts its operations accordingly.

For more expert insight and the latest market action, click here to watch this full episode of Catalysts.

This post was written by Angel Smith